Tag Archive for: RNA

BII welcomes innovative smartRNA project to Bio Studio program

BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces that it has accepted a new project into its Bio Studio program to develop a small RNA-based platform technology for treating monogenic diseases caused by reduced protein levels, primarily haploinsufficiency disorders, which constitute a significant unmet medical need. The […]

STORM Therapeutics to Present Findings on its First-in-Class METTL1 tRNA Methyltransferase Inhibitors at ESMO Targeted Anticancer Therapies Congress

Data demonstrates pharmacological inhibition of METTL1 inhibits tumour growth and reduces tRNA methylation and stability of tRNAs 22 February 2024, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, today announced that Alexandra Sapetschnig, Group Leader at STORM, will […]

Versameb Announces Publication in Molecular Therapy – Nucleic Acids Journal Demonstrating the Potential of Engineered IGF-I mRNA as a Regenerative Therapeutic

Basel, Switzerland, 12 December 2023: Versameb AG (“Versameb”), a pre-clinical stage company focused on transforming RNA therapeutics to treat unmet medical needs, today announced the publication of a scientific manuscript in the internationally recognized scientific journal, Molecular Therapy – Nucleic Acids. The paper, entitled ‘Local application of engineered insulin-like growth factor I mRNA demonstrates regenerative […]

STORM Therapeutics’ First-in-Class tRNA methyltransferase inhibitor of METTL1 to be Presented at the 65th Annual ASH Conference

Data demonstrates METTL1 inhibition in vitro at low nanomolar concentrations while displaying high selectivity over other RNA and protein methyltransferases Data provides the first proof-of-concept that pharmacological inhibition of a tRNA methyltransferase affects tumour growth in vitro and in animal models 8 December 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and […]

STORM Therapeutics Appoints Marguerite Hutchinson, J.D., as Chief Business Officer

1 November 2023, Cambridge, UK: STORM Therapeutics Ltd. (STORM), a clinical stage biotechnology company discovering and developing novel small molecule therapies targeting RNA modifying enzymes (RMEs) for oncology and other diseases, is pleased to announce the appointment of Marguerite Hutchinson, J.D., as Chief Business Officer. Read more…